Cerus Corporation (CERS)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below required floor of 3); strategy requires qualitativeScore ≥ 3 before any bullish entry, and the chart is still only a bounce attempt below the short-term trend stack.
Company overview
Cerus Corporation is a biotechnology company focused on enhancing the safety of blood transfusions through its INTERCEPT Blood System. This technology neutralizes biological threats in blood components, reducing the risk of blood-borne pathogens. Cerus markets its products globally, including systems for platelets, plasma, and red blood cells.
Fundamental
fairCerus shows improving fundamentals with revenue growth and narrowing losses but remains speculative due to ongoing GAAP losses and regulatory risks.
Cerus is growing steadily (FY2021–FY2025 revenue CAGR ~10.03%) and has narrowed losses significantly (FY2025 net margin ~-6.68%). Liquidity looks workable (current ratio ~1.83 at 6/30/2026; net debt roughly low), but the company remains GAAP unprofitable with negative interest coverage and material execution/regulatory risk around product adoption and approvals. Net: improving but still uncertain fundamentals (fundamentalScore = 3).
Sentiment
weakSentiment is weak with no significant media or retail interest, and no notable catalysts or red flags identified.
Sentiment is weak with no significant media or retail interest, and no notable catalysts or red flags identified.
Technical
weakAn oversold bounce is underway, but the trend remains bearish with the price below key short-term moving averages.
Technical score 2/5. CERS is bouncing off the 2026-07-31 earnings-gap flush and holds above the 200-day SMA and last daily VWAP, but the rebound has not repaired the short-term trend: price is still below the 20/50-day SMAs and 9/21-day EMAs, MACD is below signal and below zero, RSI is only 35.99, and ADX 27.14 says the dominant move is still down.
You’re looking at 2026-08-08 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.